Md Rezaul Karim

Dr. Md Rezaul Karim

Institute of Neuroscience, Hubei University of Medicine
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2017 in Frontiers in Neurology
Verified
Journal Article
Open access
Md Rezaul KarimMd Rezaul Karim
Md Rezaul Karim
HZHong-Yan Zhang
Hong-Yan Zhang
JYJiang Yuan
Jiang Yuan
QSQiang Sun
Qiang Sun
YWYun-Fu Wang&Ast
Yun-Fu Wang&Ast
Objective: to find out if the failure in immunotolerance of Myasthenia Gravis (MG) is a possible aspect of deduction in Breg cells and to characterize B cell subsets in MG. Methods: flow cytometry detection and ELISA assays in peripheral blood films of 10 MG patients and 10 healthy controls (HCs) were performed after isolation of B cells. The CD19+CD5+CD1d+ Breg cells percentages were measured to complement a B cell phenotype assay and frequencies of B cell subsets. The clinical outcome measures and immunological variables of patients with MG were compared with HCs. Results: patients with MG had relatively lowered percentages of CD19+CD5+CD1d+ Breg cells as compared to HCs. The production of Interleukin (IL) -10 and Transforming Growth Factor (TGF) -β1 was relatively lesser in patients with MG than HCs which were linked with more severe of MG disease status according to Myasthenia Gravis Foundation of America (MGFA) clinical classification. The reduction of cytokine production was more significant for IL-10 than TGF-β1 when compared to HCs. Conclusion: it has been observed that the reduced number of B cells are able to produce IL-10 in MG patients but lesser than compared to HCs. The Bregs reduction mainly was regarded by the severity of disease status which was highly significant and also by disease duration which was statistically significant as well. The findings of the measurement of B cell phenotype assay and frequencies of B cell subsets between MGs and HCs give us new ideas to develop B-cell mediated therapies of MG such as ① isolated B cells of MGs could be cultured with steroids eg. dexamethasone in vitro to see if it induces the CD19+CD5+CD1d+ Breg cells. ② it may observe whether induced CD19+CD5+CD1d+ Bregs have higher production of IL-10 and TGF-β1, as both are linked with disease severity. ③ after completion in vitro steps, through further research in vivo to observe whether it improves the function of MG disease status.

14 July 2020 in Research Square
Verified
Preprint
Open access
PDF file
AbuT aiub Mohammed Mohiuddin ChowdhuryAbuT aiub Mohammed Mohiuddin Chowdhury
AbuT aiub Mohammed Mohiuddin Chowdhury
MSMohammad Shahbaz
Mohammad Shahbaz
Md Rezaul KarimMd Rezaul Karim
Md Rezaul Karim
JIJohirul Islam
Johirul Islam
DGDan Guo
Dan Guo
SHShuixiang He
Shuixiang He
Background The worldwide COVID-19 pandemic was caused by a newly discovered Coronavirus. The treatment methods for COVID-19 are emerging and rapidly evolving. Existing drugs, including Ivermectin and Hydroxychloroquine, offer the hope of effective treatment in early disease. In this study, we investigated and compared outcomes of Ivermectin-Doxycycline vs. Hydroxychloroquine-Azithromycin combination therapy COVID19 patients with mild to moderate disease.Methods Patients with mild to moderate COVID-19 disease, tested positive by RT PCR for SARS-CoV-2 infection at Chakoria Upazilla Health Complex, Cox's Bazar, Bangladesh, were included in this study. Patients were divided randomly into two groups: Ivermectin 200µgm/kg single dose + Doxycycline 100 mg BID for 10days in group A, and Hydroxychloroquine 400 mg 1st day, then200mg BID for 9days + Azithromycin 500 mg daily for 5 days in group B. PCR for SARS-CoV-2 was repeated in all symptomatic patients on the second day onward without symptoms, or, for those who were asymptomatic (throughout the process), on the 5th day after taking medication and repeated every two days onward if the result is positive. Time to negative PCR and time to full symptomatic recovery was measured for each group.Results All subjects in the Ivermectin-Doxycycline group (group A) reached a negative PCR for SARS-CoV-2, at a mean of 8.93days, and all reached symptomatic recovery, at a mean of 5.93days, with 55.10% symptom-free by the 5th day. In the Hydroxychloroquine-Azithromcyin group (group B), 96.36% reached a negative PCR at a mean of 6.99days and were symptoms-free at 9.33days. Group A patients had symptoms that could have been caused by the medication in 31.67% of patients, including lethargy in 14(23.3%), nausea in 11(18.3%), and occasional vertigo in 7(11.66%) of patients. In Group B, 46.43% had symptoms that could have been caused by the medication, including 13(23.21%) mild blurring of vision and headache; 22(39.2%) increased lethargy and dizziness, 10(17.85%) occasional palpitation, and 9(16.07%) nausea and vomiting.Conclusion The Ivermectin-Doxycycline combination showed a trend toward superiority to the Hydroxychloroquine-Azithromycin combination therapy in the case of patients with mild to moderate COVID19 disease, though the difference in time to becoming symptom-free and the difference in time to negative PCR was not statistically significant.

27 May 2016 in Advances in Traditional Medicine
Verified
Journal Article
Closed access
PDF file
SBSm Faysal Bellah
Sm Faysal Bellah
ASAbdus Salam
Abdus Salam
Md Rezaul KarimMd Rezaul Karim
Md Rezaul Karim
JHJahangir Hossain
Jahangir Hossain
ASAshrafudoulla
Ashrafudoulla

1 January 2016 in Journal of Pediatric Neurosciences
Verified
Journal Article
Open access
PDF file
Md Rezaul KarimMd Rezaul Karim
Md Rezaul Karim
ASAfsarunnesa Syeda
Afsarunnesa Syeda
Objective: Petit mal epilepsy or absence seizures involve brief, sudden lapses of consciousness and most often occurs in people under age of 20 years. This study was done to find out the most likely significant age affected by petit mal epilepsy and whether they had higher rate of behavioral, educational, and social problems. Materials and Methods: We run tests on total 32 patients (male 16 and female 16) from newborns to 20 years of age. Results: The most affected ages were from 4 to 9 years and both genders were equally affected. They have higher rate of behavioral, educational, and social problems, and most likely recovering ages from the disease were from 15 to 20 years. Conclusion: These findings could contribute in diagnosis and treatment of Petit Mal Epilepsy, as it often misinterpreted as daydreaming or inattention.

7 June 2020 in Preprints.org
Verified
Preprint
Open access
XWXingxing Wu
Xingxing Wu
JYJiang Yuan
Jiang Yuan
Md Rezaul KarimMd Rezaul Karim
Md Rezaul Karim
YWYun-Fu Wang
Yun-Fu Wang
The outbreak of COVID-19 has brought unprecedented risks and challenges to everyone in the world. Myasthenia gravis is an autoimmune disease of the nervous system. Infection can worsen it and cause severe symptoms such as myasthenia crisis and respiratory failure. At present, the pandemic of COVID-19 may promote the aggravation of patients with MG. This article focuses on the respiratory management of MG patients during the epidemic of COVID-19.

22 July 2020 in Preprints.org
Verified
Preprint
Open access
MHMuhammad Anwar Hossain
Muhammad Anwar Hossain
SRSanjida Rahman
Sanjida Rahman
Md Rezaul KarimMd Rezaul Karim
Md Rezaul Karim
During this epidemic of COVID-19, children are in need of much concentration and profound love of the senior family members. Although the measures taken by the organizations are necessary to prevent the spread of the novel coronavirus, they may be causing widespread mental health issues, including depression and loneliness. Therefore, it is imperative that parents have to spend the lion-share of time with children while listening to them cordially. Parents can participate in sports with them to help them stay fit so that they can enjoy commemorating moments. However, in this additional time, the parents can also make them habituated to practice the rules of health, so does social distancing.